Clinical Trial

Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma

Name: Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma — clinical trial record (NCT06995105)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients with advanced hepatocellular carcinoma.

Trial Details

NCT Number	NCT06995105
Lead Sponsor	Zhejiang University Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions	Advanced Hepatocellular Carcinoma (HCC)
Enrollment	30 participants
Start Date	2025-04-09
Primary Completion	2027-04-01 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-29